What is the latest published CLX stock rating?

The Clorox Company is shown with Buy in the latest published report, analyzed 2026-09-20. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CLX analysis?

The full latest published report, analyzed 2026-09-20, lives at /stocks/CLX/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for CLX?

The latest published report analyzed 2026-09-20 gives CLX a fair value of USD 105 and a potential value of USD 186. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the CLX page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-09-20). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

CLX Stock: Fundamentals & Analysis | StockMarketAgent.AI

로그인 Start free

The Clorox Company (CLX)

NYSE: CLX · USD

—

StockMarketAgent Research · Analyzed 2026-09-20

Our latest published analysis: CLX rated Buy

The Clorox Company's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$105 / share

Potential value

$186 / share

Upside to FV

+26.1%

Moat

6.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$10.0B
P/E (forward)	14.2x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 14.2x
Market cap: $10.0B

Item	P1	P2	P3	P4	P5	Trend
Period	2022-06-30	2023-06-30	2024-06-30	2025-06-30	2026-06-30	Trend
Revenue	$7.11B	$7.39B	$7.09B	$7.10B	$6.72B	-1.4%
Gross profit	$2.55B	$2.91B	$3.05B	$3.21B	$2.84B	+2.8%
Operating income	$713.0M	$328.0M	$488.0M	$1.17B	$921.0M	+6.6%
Net income	$462.0M	$149.0M	$280.0M	$810.0M	$587.0M	+6.2%
EPS (diluted)	$3.73	$1.20	$2.25	$6.52	$5.54	+10.4%
EBITDA	$937.0M	$564.0M	$723.0M	$1.39B	$921.0M	-0.4%
R&D	$132.0M	$138.0M	$126.0M	$121.0M	$116.0M	-3.2%
SG&A	$954.0M	$1.18B	$1.17B	$1.12B	$317.0M	-24.1%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
BA	The Boeing Company	—	—	—	—	—	—	매도
BMY	Bristol-Myers Squibb Company	—	—	—	—	—	—	매도
CHTR	Charter Communications, Inc.	—	—	—	—	—	—	적극 매수
ADM	Archer-Daniels-Midland Company	—	—	—	—	—	—	비중 축소
BF.B	Brown-Forman Corporation Class B	—	—	—	—	—	—	매수
CAG	Conagra Brands, Inc.	—	—	—	—	—	—	적극 매수

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($104.80). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	0.5%	0.5%	1.0%	1.5%	2.0%
5.9%	$107	$107	$107	$107	$107
6.9%	$106	$106	$106	$106	$106
7.9%	$105	$105	$105	$105	$105
8.9%	$104	$104	$104	$104	$104
9.9%	$102	$102	$102	$102	$102

Scorecard

Published factor rows and weighted composite

Valuation7.5

Management7.5

Balance Sheet1.5

Profitability7.0

Revenue Growth2.5

Risk Assessment3.5

Competitive Moat6.5

Earnings Quality4.5

Capital Efficiency7.5

Weighted composite

5.3/10

Mixed

Category	Score	Reading
Valuation	7.5
Management	7.5
Balance Sheet	1.5
Profitability	7.0
Revenue Growth	2.5
Risk Assessment	3.5
Competitive Moat	6.5
Earnings Quality	4.5
Capital Efficiency	7.5

등급 이력

매월 발행된 리서치 판이 부여한 등급입니다. 등급은 분석 시점의 가격을 공정 가치와 비교한 것이며, 판단이 맞았는지에 대한 기록이 아닙니다.

연도	1월	2월	3월	4월	5월	6월	7월	8월	9월	10월	11월	12월
2026

매수

The Clorox Company (CLX)

Our latest published analysis: CLX rated Buy

Price

Financial snapshot

Fair-value bridge

Latest news · CLX

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on CLX

Frequently asked questions

등급 이력